HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A multiparametric serum marker panel as a complementary test to mammography for the diagnosis of node-negative early-stage breast cancer and DCIS in young women.

AbstractBACKGROUND:
The sensitivity of mammography for the detection of small lesions, including node-negative early-stage (T1N0) primary breast cancer (PBC) and ductal carcinoma in situ (DCIS), is significantly decreased in young patients. From a clinical standpoint, an inconclusive mammogram reflects the inability of clinicians to confidently decide whether patients should be referred for biopsy or for follow-up with repeat imaging.
METHODS:
Specific ELISAs were developed for a panel of 13 well-recognized breast autoantigens (HSP60, FKBP52, PRDX2, PPIA, MUC1, GAL3, PAK2, P53, CCNB1, PHB2, RACK1, RUVBL1, and HER2). Circulating autoantibody levels were measured in a cohort of 396 serum samples from histologically confirmed DCIS (n = 87) or T1N0 PBC (n = 153) and healthy controls (n = 156).
RESULTS:
Individually, antibodies against CCNB1, FKBP52, GAL3, PAK2, PRDX2, PPIA, P53, and MUC1 demonstrated discriminatory power between breast cancer and healthy control groups. At 90% sensitivity, the overall combined specificity of the autoantibody serum screening test was 42%. Adjustment for higher sensitivities of 95% and 99% resulted in 30% and 21% specificities, respectively (33% and 18% in T1N0 PBC and 28% and 21% in DCIS). Finally, in patients with node-negative early-stage breast cancer younger than 50 years, the autoantibody assay exhibited 59% specificity with a fixed sensitivity at 90%.
CONCLUSIONS:
Our autoantibody panel allows accurate detection of early breast cancer and DCIS, notably in younger patients.
IMPACT:
Clinical assessment of this autoantibody panel displays a potential to facilitate clinical management of early-stage breast cancer detection in cases of inconclusive mammogram.
AuthorsJérôme Lacombe, Alain Mangé, Anne-Claire Bougnoux, Ioannis Prassas, Jérôme Solassol
JournalCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (Cancer Epidemiol Biomarkers Prev) Vol. 23 Issue 9 Pg. 1834-42 (Sep 2014) ISSN: 1538-7755 [Electronic] United States
PMID24957886 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright©2014 American Association for Cancer Research.
Chemical References
  • Autoantibodies
  • Biomarkers, Tumor
  • PHB2 protein, human
  • Prohibitins
Topics
  • Adult
  • Aged
  • Autoantibodies (blood)
  • Biomarkers, Tumor (blood)
  • Breast Neoplasms (blood, diagnosis, diagnostic imaging, pathology)
  • Carcinoma, Intraductal, Noninfiltrating (blood, diagnosis, diagnostic imaging, pathology)
  • Early Detection of Cancer
  • Female
  • Humans
  • Lymphatic Metastasis
  • Mammography
  • Middle Aged
  • Prohibitins

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: